J&J's ($JNJ) Janssen Pharmaceuticals just announced a partnership involving the use of Ichor Medical Systems' TriGrid electroporation technology to deliver a DNA vaccine for hepatitis B. Ichor will receive up to $85 million via an upfront payment, R&D support and development sales milestone payments, as well as royalty payments on future licensed product sales. The device sends short electrical pulses that temporarily open cell membranes. Ichor signed a similar agreement with Pfizer ($PFE) in February for use with the pharma bigwig's preclinical cancer vaccine-based immunotherapies. More from FierceMedicalDevices